BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

RxGen, Inc. 

100 Deepwood Drive

Hamden  Connecticut    U.S.A.
Phone: 203-498-9706 Fax: 203-7762893


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology

Segment
Pharmaceuticals





 Company News
RxGen, Inc. And ProLynx Present Data On Ocular Delivery Platform 5/13/2014 12:03:48 PM
Iris Pharma and RxGen, Inc. Announce Strategic Alliance 4/19/2012 9:46:28 AM
RxGen, Inc. and miRagen Therapeutics Announce Award of National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease 8/25/2011 10:34:52 AM
RxGen, Inc. and Santaris Pharma A/S Use LNA-antimiR Technology to Antagonize the Liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol 3/27/2008 11:09:32 AM
RxGen PrimaTox, Inc And BioTrove, Inc. Announce Collaboration 1/30/2006 1:46:17 PM
RxGen, Inc. Announces The Formation Of RxGen PrimaTox, Inc., A Subsidiary Focused On Molecular Toxicology In Primates And Humans, Spencer Farr Named CEO 1/26/2006 11:08:44 AM
RxGen, Inc. Awarded Phase I Of Fast Track SBIR For Study Of Environmental Causes Of Parkinson's Disease10/19/2005 5:12:23 PM
RxGen, Inc. Provides Preclinical Research Expertise To Support The Development Of Lipid Sciences, Inc.'s (LIPD) Delipidation Technology10/19/2005 5:11:55 PM
RxGen, Inc. Awarded $1.4 Million Fast Track SBIR For Next Generation Predictive Toxicology Program, PrimaTox10/19/2005 5:11:45 PM
RxGen, Inc. Appoints Steven R. Gullans, Former US Genomics CSO, As New Chief Executive Officer10/19/2005 5:10:08 PM
12